A clinical armamentarium of marine-derived anti-cancer compounds.

Abstract:

:The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of all living organisms, the marine environment offers a rich source of natural products with potential therapeutic application. Marine organisms have evolved the enzymatic capability to produce potent chemical entities that make them promising sources of innovative cytotoxic compounds. Prominent in the identification and development of novel anti-cancer agents from marine sources is the Spanish biotechnology company, PharmaMar, which currently has a large number of oncology products in late preclinical and clinical development. These include: ecteinascidin-743 (ET-743), a marine-derived antitumor agent isolated from the Caribbean tunicate, Ecteinascidia turbinata; aplidine (Aplidin), a cyclopeptide cytotoxic agent derived from the Mediterranean tunicate, Aplidium albicans; kahalalide F, a depsipeptide isolated from the Hawaiian mollusc, Elysia rufescens; and ES-285, a molecule isolated from the mollusc, Spisula polynyma. Many of these innovative compounds have novel mechanisms of anti-tumor action that have yet to be fully elucidated.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Jimeno JM

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

S15-9

eissn

0959-4973

issn

1473-5741

journal_volume

13 Suppl 1

pub_type

杂志文章,评审
  • Long-term results of paclitaxel in FIGO stage III ovarian carcinoma.

    abstract::The combination of platinum and paclitaxel is the standard treatment of advanced ovarian carcinoma; however, recent studies have questioned the actual role of the combination as compared to either of the two agents alone. We report an open-label, two-center, phase II study of upfront paclitaxel for patients with histo...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200306000-00004

    authors: Gallardo-Rincón D,Pérez-Landeros L,Oñate-Ocaña LF,Mohar A,Calderillo G,de la Garza J,Cabrera P,Sánchez B,Dueñas-Gonzalez A

    更新日期:2003-06-01 00:00:00

  • Potential antineoplastic activity of keto-C-glycosides--a new family of cytostatic agents.

    abstract::We have examined the biological activity of keto-C-glycosides (KCGs), a new family of drugs displaying antiproliferative and cytotoxic properties on tumor cells. KCG1, the most powerful drug tested on epithelial derived neoplastic cells, was 25-125 times more cytostatic on epithelial cells than on lymphoma. By contras...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199208000-00006

    authors: Bennani-Baïti MI,Lafarge-Frayssinet C,Herscovici J,Monserret R,Antonakis K,Frayssinet C,Uriel J

    更新日期:1992-08-01 00:00:00

  • Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice.

    abstract::The in vitro antitumor activity of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, was compared with that of adriamycin (ADM) against human breast carcinomas inoculated into nude mice at the maximum tolerated dose (MTD) and clinically equivalent dose (CED). The plasma levels of NVB after intravenous inje...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199412000-00004

    authors: Tsuruo T,Inaba M,Tashiro T,Yamori T,Ohnishi Y,Ashizawa T,Sakai T,Kobayashi S,Gomi K

    更新日期:1994-12-01 00:00:00

  • DNA topoisomerase-targeting antitumor agents and drug resistance.

    abstract::A review of the chemotherapeutic agents which have been developed by targeting DNA topoisomerase I and II is presented. Camptothecins as topoisomerase I-targeting agents and newly developed topoisomerase II-targeting agents with unique properties are expected to be promising anticancer agents in the near future. An im...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199208000-00002

    authors: Takano H,Kohno K,Matsuo K,Matsuda T,Kuwano M

    更新日期:1992-08-01 00:00:00

  • Update on the current use of hormonals as therapy in advanced breast cancer.

    abstract::Hormonal agents have a confirmed role in the management of postmenopausal women with receptor-positive advanced breast cancer. Until recently, tamoxifen has been the accepted agent for treating these patients. However, accumulating evidence suggests that the new antiaromatase agents will replace the antiestrogens as t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200304000-00003

    authors: Vogel CL

    更新日期:2003-04-01 00:00:00

  • Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastases.

    abstract::Bevacizumab has been shown to be effective combined with chemotherapy for first-line treatment of advanced colorectal cancer, but little information is available about its efficacy and safety in patients who may be candidates for surgery at any time during the disease. The case history of a female patient with colorec...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000349778.09614.54

    authors: Castro-Carpeño Jd,Moyano MS,Sáenz EC,Belda-Iniesta C,Batlle JF,Barón MG

    更新日期:2009-04-01 00:00:00

  • Malignant phenotype of renal cell carcinoma cells is switched by ukrain administration in vitro.

    abstract::We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluo...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328346c7f7

    authors: Gagliano N,Pettinari L,Aureli M,Martinelli C,Colombo E,Costa F,Carminati R,Volpari T,Colombo G,Milzani A,Dalle-Donne I,Gioia M

    更新日期:2011-09-01 00:00:00

  • A palladium(II)-saccharinate complex of terpyridine exerts higher anticancer potency and less toxicity than cisplatin in a mouse allograft model.

    abstract::The main aim of this study is to assess the safety and antitumor efficacy of a palladium(II) (Pd)-saccharinate complex with terpyridine. To characterize the Pd(II) complex in vitro, its cytotoxicity was evaluated using a water-soluble tetrazolium salt cell viability assay and the mechanism of cell death was assessed b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000531

    authors: Cetin Y,Adiguzel Z,Polat HU,Akkoc T,Tas A,Cevatemre B,Celik G,Carikci B,Yilmaz VT,Ulukaya E,Acilan C

    更新日期:2017-09-01 00:00:00

  • Liver X receptor as a drug target for the treatment of breast cancer.

    abstract::Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000348

    authors: Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

    更新日期:2016-06-01 00:00:00

  • Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.

    abstract::The recombinant monoclonal antibody trastuzumab has antiproliferative effect on breast cancer (BC) cells with ErbB2 overexpression. We postulated that a mechanism able to modify ErbB2 expression enhances the antitumor effect of trastuzumab. We analyzed whether granulocyte-colony stimulating factor (G-CSF), widely used...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283050083

    authors: Cavalloni G,Sarotto I,Pignochino Y,Gammaitoni L,Migliardi G,Sgro L,Piacibello W,Risio M,Aglietta M,Leone F

    更新日期:2008-08-01 00:00:00

  • Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases.

    abstract::Amifostine is a broad-spectrum cytoprotective agent approved for protection against cisplatin toxicities and radiation-induced xerostomia; strong clinical evidence exists that amifostine protects normal mucosa and lung from radiation damage. Hypotension, nausea/vomiting, fatigue and fever/rash are the main side-effect...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200602000-00003

    authors: Koukourakis MI,Maltezos E

    更新日期:2006-02-01 00:00:00

  • Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

    abstract::Aberrant expression of the epidermal growth factor receptor (EGFR) system has been reported in a wide range of epithelial cancers. In some studies, this has also been associated with a poor prognosis and resistance to the conventional forms of therapies. These discoveries have led to the strategic development of sever...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e3283330590

    authors: Modjtahedi H,Essapen S

    更新日期:2009-11-01 00:00:00

  • Inhibition of macromolecular synthesis by cryptophycin-52.

    abstract::Cryptophycin (CP)-52, a synthetic analog of CP-1, possesses potent and selective antiproliferative activity against human solid tumors both and. Based on an algorithm developed in this laboratory using HCT-116 human colon adenocarcinoma cells, CP-52 exhibited a time- and concentration-dependent antiproliferative effec...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200211000-00010

    authors: Subramanian B,Nakeff A,Media JE,Wiegand RA,Valeriote FA

    更新日期:2002-11-01 00:00:00

  • PC cell-derived growth factor overexpression promotes proliferation and survival of laryngeal carcinoma.

    abstract::PC cell-derived growth factor is a novel growth factor for tumor formation and progression. No comprehensive literature concerning PC cell-derived growth factor expression status and its biological function in squamous cell carcinoma, especially in the larynx, is, however, available. The target of this study is to eva...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000236315.96574.58

    authors: Kong WJ,Zhang SL,Chen X,Zhang S,Wang YJ,Zhang D,Sun Y

    更新日期:2007-01-01 00:00:00

  • Doxorubicin induces apoptosis in Jurkat cells by mitochondria-dependent and mitochondria-independent mechanisms under normoxic and hypoxic conditions.

    abstract::In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. Using in-cell western analysis, immunofluorescence, flow cytometry analysis, and biochemical in...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000223

    authors: Mendivil-Perez M,Velez-Pardo C,Jimenez-Del-Rio M

    更新日期:2015-07-01 00:00:00

  • MicroRNA-301b and its target gene synaptosome-associated protein 91 as important modulators in esophageal cancer: functional experiments.

    abstract::The aim of this study was to probe the influence of microRNA-301b (miR-301b) in esophageal cancer pathogenesis. Based on the data acquired from The Cancer Genome Atlas database, we found that miR-301b was highly expressed in esophageal cancer tissues and high expression of miR-301b was related to worse prognosis in pa...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000893

    authors: Pan F,Chen M,Song XY,Yang JD

    更新日期:2020-04-01 00:00:00

  • Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines.

    abstract::It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the an...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199605000-00016

    authors: Maki A,Mohammad R,Raza S,Saleh M,Govindaraju KD,Pettit GR,al-Katib A

    更新日期:1996-05-01 00:00:00

  • The impact of taxanes on the management of genitourinary cancers.

    abstract::Taxanes have had a profound impact on the management of genitourinary tumors. In the perioperative and metastatic setting in bladder cancer, taxanes such as paclitaxel have an established role in combination chemotherapy strategies to improve survival. In metastatic prostate cancer, docetaxel was the only treatment, u...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000088

    authors: Balar AV

    更新日期:2014-05-01 00:00:00

  • Tumor-specific DNA in plasma of breast cancer patients.

    abstract::The presence of DNA fragments circulating in cancer patients was described a number of years ago. The mere presence of DNA in the circulation is not indicative of cancer. However, there are reports that apoptosis and necrosis of the cancer cells can increase the levels of circulating DNA. The study of plasma DNA with ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200204000-00003

    authors: Shao ZM,Nguyen M

    更新日期:2002-04-01 00:00:00

  • Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.

    abstract::Our previous studies have shown that arsenic trioxide (As2O3), a novel anti-cancer agent, may be active against urothelial carcinomas. A series of bladder urothelial carcinoma cells with progressive As2O3 resistance were established and studied to reveal molecular events in relation to the mechanisms of resistance to ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200409000-00007

    authors: Hour TC,Huang CY,Lin CC,Chen J,Guan JY,Lee JM,Pu YS

    更新日期:2004-09-01 00:00:00

  • Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells.

    abstract::Analog II (1,1-dichloro-cis-2,3-diarylcyclopropane), previously shown to be a pure antiestrogen in mice, was examined for potential antitumor activity on human breast cancer cells in culture. In this study, Analog II produced a dose-related antiproliferative effect on the growth of estrogen receptor (ER)-positive MCF-...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199711000-00008

    authors: Jain PT,Rajah TT,Pento JT

    更新日期:1997-11-01 00:00:00

  • Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle.

    abstract::The aim of this study was to identify the most potent quinoline-based anti-infectives for the treatment of multiple myeloma (MM) and to understand the molecular mechanisms. A small-scale screen against a panel of marketed quinoline-based drugs was performed in MM cell lines. Cell apoptosis was examined by flow cytomet...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000466

    authors: Mao H,Du Y,Zhang Z,Cao B,Zhao J,Zhou H,Mao X

    更新日期:2017-04-01 00:00:00

  • No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone.

    abstract::In a recent study we demonstrated that recombinant human growth hormone (r-hGH; Saizen) delayed tumor-induced cachexia in human tumor xenografts in vivo. Such a therapeutic effect could have a great impact in the supportive care of advanced cancer patients. Before large clinical studies are initiated possible growth s...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200009000-00011

    authors: Fiebig HH,Dengler W,Hendriks HR

    更新日期:2000-09-01 00:00:00

  • In-vitro and in-vivo investigations into the carbene-gold anticancer drug candidates NHC*-Au-SCSNMe2 and NHC*-Au-S-GLUC against advanced prostate cancer PC3.

    abstract::The anticancer drug candidates 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene gold(I) dimethylamino dithiocarbamate and 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl-1-thiolate derivative exhibited nanomolar in-vitro activity against prostate cancer cells advanced prostate cancer (PC3) and micromolar inhibition of mammalian...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000930

    authors: Walther W,Althagafi D,Curran D,O'Beirne C,Mc Carthy C,Ott I,Basu U,Büttner B,Sterner-Kock A,Müller-Bunz H,Sánchez-Sanz G,Zhu X,Tacke M

    更新日期:2020-08-01 00:00:00

  • A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).

    abstract::In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetin...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328350737d

    authors: Boers-Sonderen MJ,Desar IM,Blokx W,Timmer-Bonte JN,van Herpen CM

    更新日期:2012-08-01 00:00:00

  • The signaling axis of Rac1-TFEB regulates autophagy and tumorigenesis.

    abstract::Macroautophagy (hereafter referred to as autophagy) plays essential roles in cellular and organismal homeostasis. Transcription factor EB (TFEB) is a master regulator of autophagy and lysosome biogenesis. It is not fully understood how the function of TFEB in autophagy pathway is regulated. Here, we show that Rac1 GTP...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000816

    authors: Ma L,Ma Y,Zhang Z,Wang Q,Liu X

    更新日期:2019-11-01 00:00:00

  • Vitamin C suppresses the cisplatin toxicity on blood platelets.

    abstract::The effects of vitamin C on the oxidative stress in blood platelets induced by cisplatin were studied. In the presence of vitamin C we measured in blood platelets the production of thiobarbituric acid reactive substances (TBARS), the generation of superoxide radicals (O2*-), other reactive oxygen species (H2O2, single...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200007000-00010

    authors: Olas B,Wachowicz B,Buczyński A

    更新日期:2000-07-01 00:00:00

  • Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.

    abstract::Neoadjuvant TPF (docetaxel, cisplatin, 5-fluorouracil), followed by radiotherapy or chemoradiotherapy with weekly carboplatin, increases overall survival and organ preservation. We assessed whether TPF could be used in routine practice and whether radiotherapy potentiated with cisplatin or cetuximab was feasible and c...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CAD.0b013e328360b9d6

    authors: Fayette J,Bonnin N,Ferlay C,Lallemant B,Ramade A,Favrel V,Zrounba P,Chabaud S,Pommier P,Poupart M,Céruse P

    更新日期:2013-07-01 00:00:00

  • Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis.

    abstract::Prostaglandin E2 (PGE2) has been shown to play an important role in tumor development and progression. PGE2 mediates its biological activity by binding any one of four prostanoid receptors (EP1 through EP4). The present study was designed to determine the role of the EP2 receptor during the proliferation and apoptosis...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835a4dac

    authors: Hu S,Sun W,Wei W,Wang D,Jin J,Wu J,Chen J,Wu H,Wang Q

    更新日期:2013-02-01 00:00:00

  • Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.

    abstract::Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000592

    authors: Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

    更新日期:2018-04-01 00:00:00